Apellis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APLS Nasdaq 2836 apellis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Feb 11th, 2026 9:11 am
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - Feb 10th, 2026 5:00 am
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Jan 29th, 2026 10:24 pm
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Jan 29th, 2026 5:05 am
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Jan 27th, 2026 4:02 pm
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction - Jan 27th, 2026 6:14 am
Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says - Jan 21st, 2026 9:19 am
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - Jan 17th, 2026 3:36 am
Sector Update: Health Care Stocks Mixed Premarket Friday - Jan 16th, 2026 7:22 am
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Jan 15th, 2026 9:16 am
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Jan 13th, 2026 2:15 pm
A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion - Jan 13th, 2026 2:10 am
JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won - Jan 12th, 2026 2:18 pm
Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference - Jan 12th, 2026 1:37 pm
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Jan 12th, 2026 5:00 am
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:00 am
Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN - Dec 12th, 2025 6:12 am
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Dec 5th, 2025 2:07 pm
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? - Dec 4th, 2025 9:30 am
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - Dec 3rd, 2025 3:05 pm